Overview
Continuing education credits or Certificate Program units are not available for archived webinars.
Key FDA representatives discussed the background, causes, trends, impact and prevention of drug shortages. Original webinar participants had the opportunity to discuss their questions and gain more insight during an interactive panel discussion and chat features.
Archived Webinar available through June 5, 2013
Featured Topics
- Causes/Trends/FDA role in prevention & mitigation
- FDA guidance on notification
- Collaborations/Communication with industry and stakeholder groups
- Panel Discussion and Q&A
Who Should Attend
• Manufacturers
• Distributers
• Purchasing Organizations
• Regulatory Bodies
• Policy Makers
• Regulatory Affairs
• Clinical Safety/Pharmacovigilance
• Pricing/Reimbursement
• Public Policy/Law/Corp. Compliance
• Quality Assurance/Quality Control
• Strategic Planning
• Sales and Marketing
Learning Objectives
At the conclusion of this webinar, participants should be able to:
- Discuss the background, causes and recent trends of drug shortages
- Translate the FDA Guidance on notification and their role in prevention and mitigation
- Describe how FDA is collaborating and communicating with industry and Stakeholder Groups to prevent and mitigate drug shortages
Special Offers
Save up to 20 percent by registering online in one transaction for multiple webinars in this series. (Special pricing valid for online registrations by individuals and groups.)
Contact Information
For questions about Archived Webinars
Carolyn Callahan
DIA North America
Phone +1.215.442.6194
Fax +1.215.442.6199
Carolyn.Callahan@diahome.org
Technical Requirements
Click
here for minimum system requirements.
Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.